AAVAS Financiers Ltd Q1 FY27 Results Analysis: PAT Surges 23%, Credit Cost Jumps 92%

CompoundingAI Research Updated July 21, 2026 2 min read
Neutral

AAVAS Financiers Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 708.72 Cr (+12.93% YoY) and PAT growth of +23.01% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 21, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 708.72 Cr (+12.93% YoY)
PAT (Q1)Rs. 171.27 Cr (+23.01% YoY)
EPS (Q1)Rs. 21.60 (+22.80% YoY)
Market capRs. 12,060.79 Cr
CMPRs. 1,521.70

Quarter Snapshot

AAVAS delivered strong 23% YoY PAT growth and improved cost-income ratio to 44.08%, but asset quality slightly deteriorated (GNPA up to 1.11%) and credit cost jumped 92% QoQ. The CFO and CRO resignations and credit rating watch add uncertainty to the near-term outlook.

Key Investment Insights

Key Positives

  • Revenue grew 12.93% YoY to Rs.708.72 Cr, driven by 12.30% YoY growth in interest income.
  • Net Interest Income grew 16.66% YoY to Rs.323.84 Cr, outpacing total revenue growth.
  • Pre-Provision Operating Profit grew 22.33% YoY to Rs.232.90 Cr.
  • Profit After Tax grew 23.01% YoY to Rs.171.27 Cr, with EPS at Rs.21.60 (up 22.80% YoY).
  • Cost-to-income ratio improved to 44.08% from 46.61% a year ago.
  • Capital Adequacy Ratio (CRAR) remained strong at 44.66%.
  • No auditor qualifications or adverse observations in the review report.

Risk Factors

  • Gross NPA ratio edged up to 1.11% from 1.05% in Q4 FY26, with Net NPA rising to 0.71% from 0.68%.
  • Impairment on financial instruments jumped 92.31% QoQ to Rs.12.80 Cr, signalling rising credit cost.
  • Finance costs rose 7.01% QoQ, indicating the cost-of-funds tailwind is moderating.
  • CFO and CRO resigned effective September 21, 2026, with interim appointments, creating leadership uncertainty.
  • Credit ratings placed on 'Rating Watch with Developing Implications' by CARE and ICRA effective July 1, 2026.
Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.

Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings

Login Now